New-onset IgG autoantibodies in hospitalized patients with COVID-19.
Sarah Esther Chang,Allan Feng,Wenzhao Meng,Sokratis A. Apostolidis,Elisabeth Mack,Maja Artandi,Linda Barman,Kate Bennett,Saborni Chakraborty,Iris Chang,Peggie Cheung,Sharon Chinthrajah,Shaurya Dhingra,Evan Do,Amanda Finck,Andrew Gaano,Reinhard Geßner,Heather M. Giannini,Joyce Gonzalez,Sarah Greib,Margrit Gündisch,Alex Ren Hsu,Alex J. Kuo,Monali Manohar,Rong Mao,Indira Neeli,Andreas Neubauer,Oluwatosin Oniyide,Abigail E. Powell,Rajan Puri,Harald Renz,Jeffrey M. Schapiro,Payton A. Weidenbacher,Richard Wittman,Neera Ahuja,Ho-Ryun Chung,Prasanna Jagannathan,Judith A. James,Peter S. Kim,Peter S. Kim,Nuala J. Meyer,Kari C. Nadeau,Marko Z. Radic,William H. Robinson,William H. Robinson,Upinder Singh,Taia T. Wang,E. John Wherry,Chrysanthi Skevaki,Eline T. Luning Prak,Paul J. Utz +50 more
Reads0
Chats0
TLDR
In this article, three protein arrays were developed to measure IgG autoantibodies associated with connective tissue diseases, anti-cytokine antibodies, and anti-viral antibody responses in serum from 147 hospitalized COVID-19 patients.Abstract:
COVID-19 is associated with a wide range of clinical manifestations, including autoimmune features and autoantibody production. Here we develop three protein arrays to measure IgG autoantibodies associated with connective tissue diseases, anti-cytokine antibodies, and anti-viral antibody responses in serum from 147 hospitalized COVID-19 patients. Autoantibodies are identified in approximately 50% of patients but in less than 15% of healthy controls. When present, autoantibodies largely target autoantigens associated with rare disorders such as myositis, systemic sclerosis and overlap syndromes. A subset of autoantibodies targeting traditional autoantigens or cytokines develop de novo following SARS-CoV-2 infection. Autoantibodies track with longitudinal development of IgG antibodies recognizing SARS-CoV-2 structural proteins and a subset of non-structural proteins, but not proteins from influenza, seasonal coronaviruses or other pathogenic viruses. We conclude that SARS-CoV-2 causes development of new-onset IgG autoantibodies in a significant proportion of hospitalized COVID-19 patients and are positively correlated with immune responses to SARS-CoV-2 proteins.read more
Citations
More filters
Journal ArticleDOI
Autoantibodies Neutralizing Type I IFNs in the Bronchoalveolar Lavage of at Least 10% of Patients During Life-Threatening COVID-19 Pneumonia
Quentin Philippot,Arnaud Fekkar,A Gervais,Tom Le Voyer,Leonoor S. Boers,Clement Conil,Lucy Bizien,Justin de Brabander,JanWillem Duitman,Jérémie Rosain,Marion Blaize,Mélanie Migaud,Maxime Jeljeli,Boualem Hammadi,Aurore Desmons,Astrid Marchal,Esther J. Nossent,Anno Saris,Heder J de Vries,Lilian J. Meijboom,Siebe G Blok,Alex R. Schuurman,Tom D Y Reijnders,Floor Hugenholtz,Juan J. Garcia Vallejo,Hetty J. Bontkes,Alexander P.J. Vlaar,J. Wiersinga,René Lutter,T. van der Poll,Harm Jan Bogaard,Robert F. J. Kullberg,Shiqi Zhang,Leo M. A. Heunks,Pieter R. Tuinman,Peter I. Bonta,Laurent Abel,Saleh Al-Muhsen,Andrés Augusto Arias,Dusan Bogunovic,Alexandre Bolze,Ahmed Aziz Bousfiha,Davood Mansouri,Isabelle Meyts,Rebeca Pérez de Diego,Vanessa Sancho-Shimizu,András N Spaan,Stuart G. Tangye,Shen-ying Zhang,Helen C. Su,Julien Mayaux,Qian Zhang,Emmanuelle Jouanguy,Raphael Borie,Bruno Crestani,Charles-Edouard Luyt,Homa Adle-Biassette,Damien Sène,Bruno Mégarbane,Aurélie Cobat,Paul Bastard,Lieuwe D. J. Bos,Jean-Laurent Casanova,Anne Puel +63 more
TL;DR: In this paper , the presence of auto-antibodies neutralizing type I interferons in the bronchoalveolar lavage (BAL) of 54 of the 415 unvaccinated patients (13%) with life-threatening COVID-19 pneumonia tested was reported.
Journal ArticleDOI
COVID-19 Infection: The Virus and Its Origin, the Variants, the Immune Defense, the Multiorgan Autoimmune Reactions, and the Targeted Treatments
Vu T. Nguyen,Lawrence S. Chan +1 more
TL;DR: In this article , the authors performed a thorough review of the subject in order to come to a better understanding of the origin of the virus, its mutations and their corresponding health effects, its pathophysiology, and its responses to therapeutic intervention.
Journal ArticleDOI
Incident autoimmune diseases in association with SARS-CoV-2 infection: a matched cohort study
TL;DR: In this paper , a large-scale study was conducted to investigate whether the risk of developing an incident autoimmune disease is increased in patients with prior COVID-19 disease compared to those without.
Journal ArticleDOI
Observational study of factors associated with morbidity and mortality from COVID-19 in Lebanon, 2020–2021
Moni Nader,Omar Zmerli,Daniel E. Platt,Hamdan Ahmed Hamdan,Salwa Hamdash,Rami Abi Tayeh,Jad Azar,Diana Kadi,Youssef Sultan,T Bazarbachi,Gilbert Karayakoupoglou,Pierre Zalloua,Eid Azar +12 more
TL;DR: The data show that high creatinine levels were significantly associated with fatality in the COVID-19 study patients, underscoring the importance of kidney function as a main modulator of SARS-CoV-2 morbidity and favor a careful and proactive management of patients with elevated creat inine levels on admission.
Journal ArticleDOI
Antinuclear Antibody Positivity in Patients With Hair Loss After COVID-19 Infection
TL;DR: In this paper , the authors investigated the relationship between COVID-19-related hair loss and antinuclear antibody (ANA) positivity and patterns, and found that hair loss is one of the most common disorders after coronavirus disease 2019 infection.
References
More filters
Journal Article
R: A language and environment for statistical computing.
TL;DR: Copyright (©) 1999–2012 R Foundation for Statistical Computing; permission is granted to make and distribute verbatim copies of this manual provided the copyright notice and permission notice are preserved on all copies.
Journal ArticleDOI
Clinical Characteristics of Coronavirus Disease 2019 in China.
Wei-jie Guan,Zhengyi Ni,Yu Hu,Wenhua Liang,Chun-Quan Ou,Jianxing He,Lei Liu,Hong Shan,Chunliang Lei,David S.C. Hui,Bin Du,Lanjuan Li,Guang Zeng,Kowk-Yung Yuen,Ruchong Chen,Chun-Li Tang,Tao Wang,Ping-Yan Chen,Jie Xiang,Shiyue Li,Jinlin Wang,Zi-jing Liang,Yi-xiang Peng,Li Wei,Yong Liu,Ya-hua Hu,Peng Peng,Jian-ming Wang,Ji-yang Liu,Zhong Chen,Gang Li,Zhi-jian Zheng,Shao-qin Qiu,Jie Luo,Chang-jiang Ye,Shao-yong Zhu,Nanshan Zhong +36 more
TL;DR: During the first 2 months of the current outbreak, Covid-19 spread rapidly throughout China and caused varying degrees of illness, and patients often presented without fever, and many did not have abnormal radiologic findings.
Journal ArticleDOI
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
Nanshan Chen,Min Zhou,Xuan Dong,Jie-Ming Qu,Fengyun Gong,Yang Han,Yang Qiu,Jingli Wang,Ying Liu,Yuan Wei,Jia'an Xia,Ting Yu,Xinxin Zhang,Li Zhang +13 more
TL;DR: Characteristics of patients who died were in line with the MuLBSTA score, an early warning model for predicting mortality in viral pneumonia, and further investigation is needed to explore the applicability of the Mu LBSTA scores in predicting the risk of mortality in 2019-nCoV infection.
Journal ArticleDOI
Persistent Symptoms in Patients After Acute COVID-19.
TL;DR: This case series describes COVID-19 symptoms persisting a mean of 60 days after onset among Italian patients previously discharged from CO VID-19 hospitalization.
Journal ArticleDOI
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients.
Jérôme Hadjadj,Nader Yatim,Laura Barnabei,Aurélien Corneau,Jeremy Boussier,Nikaïa Smith,Hélène Péré,Bruno Charbit,Vincent Bondet,Camille Chenevier-Gobeaux,Paul Breillat,Nicolas Carlier,Rémy Gauzit,Caroline Morbieu,Frédéric Pène,Nathalie Marin,Nicolas Roche,Tali Anne Szwebel,Sarah H. Merkling,Jean-Marc Treluyer,David Veyer,Luc Mouthon,Catherine Blanc,Pierre-Louis Tharaux,Flore Rozenberg,Alain Fischer,Alain Fischer,Alain Fischer,Darragh Duffy,Frédéric Rieux-Laucat,Solen Kernéis,Solen Kernéis,Benjamin Terrier +32 more
TL;DR: The results of this trio of studies suggest that the location, timing, and duration of IFN exposure are critical parameters underlying the success or failure of therapeutics for viral respiratory infections.
Related Papers (5)
New-Onset IgG Autoantibodies in Hospitalized Patients with COVID-19
Sarah Esther Chang,Allan Feng,Wenzhao Meng,Sokratis A. Apostolidis,Elisabeth Mack,Maja Artandi,Linda Barman,Kate Bennett,Saborni Chakraborty,Iris Chang,Peggie Cheung,Sharon Chinthrajah,Shaurya Dhingra,Evan Do,Amanda Finck,Andrew Gaano,Reinhard Geßner,Heather M. Giannini,Joyce Gonzalez,Sarah Greib,Margrit Gündisch,Alex Ren Hsu,Alex J. Kuo,Monali Manohar,Rong Mao,Indira Neeli,Andreas Neubauer,Oluwatosin Oniyide,Abigail E. Powell,Rajan Puri,Harald Renz,Jeffrey M. Schapiro,Payton A. Weidenbacher,Richard Wittman,Neera Ahuja,Ho-Ryun Chung,Prasanna Jagannathan,Judith A. James,Peter S. Kim,Nuala J. Meyer,Kari C. Nadeau,Marko Z. Radic,William H. Robinson,William H. Robinson,Upinder Singh,Taia T. Wang,E. John Wherry,Chrysanthi Skevaki,Eline T. Luning Prak,Paul J. Utz +49 more